Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to a therapeutic treatment or prevention of viral infections such as, for example, COVID-19. In one aspect, the therapeutic treatment combines the administration of doxycycline and/or chemically-modified tetracyclines with resveratrol and ivermectin. In another aspect, the disclosed treatment offers anti-inflammatory effects, can combat the effects of reactive oxygen species, and can inhibit the activity of matrix metalloproteinase enzymes; these combined effects may, in some aspects, be useful in preventing or mediating the effects of the cytokine storm that is associated with poor COVID-19 outcomes including death. In some aspects, dosages of the treatment can be modified to account for COVID-19 comorbidities including, but not limited to, such conditions as diabetes or hypertension.

Abstract: The use of PREVORA brand topical dental solution (100 mg/ml chlorhexidine) sold by CHX Technologies, Inc., Toronto, Canada, to treat and/or prevent the advance of both dental decay (caries) and periodontal disease, simultaneously and in one procedure, that can easily be accomplished by a dental professional or a medical assistant. Chronic periodontitis and/or caries, the result of an imbalance of the microbial composition of the biofilm on the teeth, at the gum line or under the gum line, can be treated by the application of PREVORA, following standard oral cleaning and debriding of plaque at or below the gum line, to restore the balance of the biofilm to more normal, symbiotic composition. This treatment method is particularly useful in conjunction with the medical management of chronic diseases, such as type 2 diabetes, chronic obstructive pulmonary disease, cardiovascular disease, and the like, which have been associated with periodontopathogens.